BMEA - Biomea Fusion, Inc.

2.005
-0.115   -5.736%

Share volume: 1,011,006
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$2.12
-0.12
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
28%
Profitability 0%
Dept financing 31%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.82%
1 Month
-19.96%
3 Months
-53.04%
6 Months
-82.41%
1 Year
-83.97%
2 Year
-91.93%
Key data
Stock price
$2.00
P/E Ratio 
0.00
DAY RANGE
$1.89 - $2.21
EPS 
-$3.99
52 WEEK RANGE
$1.86 - $13.66
52 WEEK CHANGE
-$84.34
MARKET CAP 
365.723 M
YIELD 
N/A
SHARES OUTSTANDING 
36.210 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-01-2025
BETA 
2.62
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$882,802
AVERAGE 30 VOLUME 
$721,982
Company detail
CEO: Thomas Butler
Region: US
Website: biomeafusion.com
Employees: 50
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Biomea Fusion, Inc. focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.

Recent news
loading